6:30 AM SIGN-IN & BREAKFAST • 7:00 AM - 8:30 AM

BANDOL 2 (NEW WYNN SPACE)

CE: Myelodysplastic Syndrome and Myelodysplastic-associated Anemia: Exploring Clinical Treatment Updates

Myelodysplastic syndromes (MDSs) are a group of relatively rare heterogeneous diseases that affect the blood and bone marrow. Anemia is one of the most common findings in MDS, often requiring blood transfusions to improve quality of life and patient outcomes. Consequences of transfusions include iron overload, necessitating the use of iron chelators. An agent with a new erythroid maturation mechanism has been approved in the past 12 months and additional agents with promising outcomes are in the pipeline. These agents could mitigate the need for transfusions, thereby diminishing the consequences of iron overload in this patient population. This program will examine MDS, the complications of MDS-associated anemia, and innovative treatments for addressing this clinical need. Discussion will include addressing the considerable economic burden of MDS as direct medical resource utilization and treatment and supportive care costs, such as red blood cell transfusions, account for a significant portion of MDS-related costs.

Speakers

Anthony Perissinotti

Bhavesh Shah

Asembia

200 Park Avenue, Suite 300 
Florham Park, NJ 07932

973.564.8004

asembia.com

info@asembiasummit.com

SIGN UP FOR SUMMIT UPDATES

Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

Terms & Conditions © 2019 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.

CONNECT WITH US

  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos
SummitLogo_2020_White.png